Number 912 • November 2020

Product supply shortages addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by Taro Pharmaceuticals Inc. that the shortage for Taro-Clotrimazole/Betamethasone 1% Topical Cream (DIN 02496410) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **December 2, 2020.** The following grouping was removed from the Critical Supply Product List **November 3, 2020.**

BETAMETHASONE DIPROPIONATE/ CLOTRIMAZOLE

0.05 % / 1 % TOPICAL CREAM

 00002496410
 TARO-CLOTRIMAZOLE/ BETAMETHASONE
 TAR
 \$ 0.6964

 00000611174
 LOTRIDERM
 MFC
 \$ 0.8193

Alberta Blue Cross has been advised by Apotex Inc. that the shortage for Apo-Phenytoin Sodium 100 mg Capsule (DIN 02460912) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **December 14, 2020**. The following grouping was removed from the Critical Supply Product List **November 13, 2020**.

PHENYTOIN SODIUM

100 MG CAPSULE

 00002460912
 APO-PHENYTOIN SODIUM
 APX
 \$ 0.0665

 00000022780
 DILANTIN
 PFI
 \$ 0.0913

Alberta Blue Cross has been advised by Apotex Inc. and Auro Pharma Inc. that the shortages for Apo-Quinapril/HCTZ 20 mg/25 mg Tablet (DIN 02408783) and Auro-Quinapril HCTZ 20 mg/25 mg Tablet (DIN 02473321) respectively, have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **December 14, 2020**. The following grouping was removed from the Critical Supply Product List **November 13, 2020**.

QUINAPRIL HYDROCHLOROTHIAZIDE

20 MG / 25 MG TABLET

00002408783	APO-QUINAPRIL / HCTZ	APX	\$ 0.4602
00002473321	AURO-QUINAPRIL HCTZ	AUR	\$ 0.4602
00002237369	ACCURETIC 20/25	PFI	\$0.9423

Alberta Blue Cross has been advised by Apotex Inc. and Auro Pharma Inc. that the shortages for Apo-Quinapril/HCTZ 20 mg/12.5 mg Tablet (DIN 02408775) and Auro-Quinapril HCTZ 20 mg/12.5 mg Tablet (DIN 02473305) respectively, have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **December 16, 2020**. The following grouping was removed from the Critical Supply Product List **November 16, 2020**.

QUINAPRIL HYDROCHLOROTHIAZIDE

20 MG / 12.5 MG TABLET

00002408774	APO-QUINAPRIL/HCTZ	APX	\$ 0.4786
00002473305	AURO-QUINAPRIL HCTZ	AUR	\$ 0.4786
00002237368	ACCURETIC 20/12.5	PFI	\$ 0.9840

Temporary benefits added to the Alberta Drug Benefit List (ADBL)

Due to the unavailability of Apo-Ibuprofen 300 mg Tablet (DIN 00441651) and Apo-Ibuprofen 600 mg Tablet (DIN 00585114), manufactured by Apotex Inc., Advil 200 mg Tablet (DIN 01933558) manufactured by Pfizer Consumer Healthcare will be considered as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

As of **October 29, 2020**, all claims for Advil 200 mg Tablet (DIN 01933558) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at https://www.ab.bluecross.ca/providers/pharmacy-home.php.

If this situation continues to be a long-term matter, then this product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics and must be approved by the Minister of Health for addition to the *ADBL* in order to remain as a benefit.

Due to the unavailability of Xylocaine 2% Topical Jelly (DIN 00001694) manufactured by Aspen Pharmacare Canada Inc., Jelido 2% Topical Jelly (DIN 02469146) manufactured by Pendopharm Inc. will be considered as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

As of **November 10, 2020**, all claims for Jelido 2% Topical Jelly (DIN 02469146) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL*) until further notice. The *ABCDPL* is available online at https://www.ab.bluecross.ca/providers/pharmacy-home.php.

If this situation continues to be a long-term matter, then this product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics and must be approved by the Minister of Health for addition to the *ADBL* in order to remain as a benefit.

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free) **FAX 780-498-8406** (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. **Visit ab.bluecross.ca/providers/pharmacy-home.php**



